News Sentiment

VIR sentiment intelligence

Vir Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.96 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.8% over one week, +15.7% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.8% Price digesting
Trend fit Trend active 15.7% over four weeks
Fair value 19.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 43
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
MarketBeat 7
TradingView 6
Stock Titan 5
simplywall.st 5
TradingKey 4
Investing.com 3
Business Wire 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 24
Analyst action 3
Deals and strategy 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Insider Monkey Direct company coverage

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?

The article summarizes a bullish thesis on Vir Biotechnology, Inc. (VIR) from Valueinvestorsclub.com, highlighting its lead asset VIR-5500 for metastatic castration-resistant prostate cancer. The therapy shows promising Phase 1 data with high response rates and reduced toxicity,

Tone
Neutral 50/100
Event
Macro sensitivity
Published
07 Jun 2026 20:25
Source
Insider Monkey
Stocktwits Direct company coverage

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Vir Biotechnology Inc. (VIR) saw its stock surge by 60% pre-market after strong fourth-quarter earnings, positive Phase 1 cancer therapy data for VIR-5500, and a new partnership with Astellas Pharma. Analysts responded with upgrades and increased price targets, signaling strong c

Tone
Positive 94/100
Event
Earnings
Published
06 Jun 2026 09:39
Source
Stocktwits